Surabhi Dangi-Garimella,


Comparing CVD Risk Factors Associated With Adjuvant Endocrine Therapies

May 02, 2016

A retrospective analysis conducted by researchers at Kaiser Permanente and UCLA has concluded that patients with breast cancer treated with aromatase inhibitors (AIs) as adjuvant endocrine therapy were at equal risk of serious cardiovascular disease (CVD) events as those treated with tamoxifen.